Alcon Inc. (NYSE:ALC) is reporting second quarter financial results on Tuesday 18th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ALC is expected to report 2Q20 loss of $ 0.15 per share from revenue of $ 1136.96 million.
For the full year, analysts anticipate top line of $ 6576.58 million, while looking forward to income of $ 1.06 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 7,730.00 million ~ $ 7,804.00 million, where as bottomline are predicted in a range of $ 1.95 ~ $ 2.05 per share
Click Here For More Historical Outlooks Of Alcon Inc.
Previous Quarter Performance
Alcon Inc. posted income for the first quarter of $ 0.45 per share, from the revenue of $ 1,822.00 million. The quarterly earnings declined 11.76 percent while revenues increased 2.53 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.35 per share from $ 1705.98 million in revenue. The bottom line results beat street analysts by $ 0.1 or 28.57 percent, at the same time, top line results outshined analysts by $ 116.02 million or 6.80 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Alcon Inc.
Stock Performance
According to the previous trading day, closing price of ALC was $ 61.65, representing a 56.59 % increase from the 52 week low of $ 39.37 and a 5.69 % decrease over the 52 week high of $ 65.37.
The company has a market capital of $ 30.02 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ALC” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Alcon, Inc. develops and manufactures eye care products for eye care professionals and their patients. It offers surgical products, which include technologies and devices for cataract, retinal, glaucoma, and refractive surgery; advanced technology intraocular lenses to treat cataracts and refractive errors, such as presbyopia and astigmatism; and advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery.
